These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 36274381)
1. Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs. Roessner A; Franke S; Schreier J; Ullmann S; Karras F; Jechorek D Pathol Res Pract; 2022 Nov; 239():154172. PubMed ID: 36274381 [TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis. Azzi G; Velez M; Mathias-Machado MC Curr Opin Oncol; 2014 Jul; 26(4):403-7. PubMed ID: 24867810 [TBL] [Abstract][Full Text] [Related]
3. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma. Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487 [TBL] [Abstract][Full Text] [Related]
4. Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. M Gagné L; Boulay K; Topisirovic I; Huot MÉ; Mallette FA Trends Cell Biol; 2017 Oct; 27(10):738-752. PubMed ID: 28711227 [TBL] [Abstract][Full Text] [Related]
5. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Chang S; Yim S; Park H Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981 [TBL] [Abstract][Full Text] [Related]
6. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816 [TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas. Han CH; Batchelor TT Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010 [TBL] [Abstract][Full Text] [Related]
8. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase. Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236 [TBL] [Abstract][Full Text] [Related]
9. Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth. Li L; Hu X; Eid JE; Rosenberg AE; Wilky BA; Ban Y; Sun X; Galoian K; DeSalvo J; Yue J; Chen XS; Blonska M; Trent JC Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935911 [TBL] [Abstract][Full Text] [Related]
10. IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract. Tallegas M; Miquelestorena-Standley É; Labit-Bouvier C; Badoual C; Francois A; Gomez-Brouchet A; Aubert S; Collin C; Tallet A; de Pinieux G Hum Pathol; 2019 Feb; 84():183-191. PubMed ID: 30296521 [TBL] [Abstract][Full Text] [Related]
11. Distinct IDH1/2-associated Methylation Profile and Enrichment of Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116 [TBL] [Abstract][Full Text] [Related]